Economic outcomes associated with atypical antipsychotics in bipolar disorder: A systematic review

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 6, 2007, Pages 419-428

  Fleurence, Rachael L ^a,e   Chatterton, Mary Lou ^b   Dixon, Julia M ^a   Rajagopalan, Kitty ^c,d  

^a Center for Health Outcomes Research   (United States)

^b MLG Consulting Services Inc   (United States)

^c ASTRAZENECA   (United Kingdom)

^d BIOGEN   (United States)

^e UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECONOMIC ASPECT; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

EID: 37249009068     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0603     Document Type: Review

References (43)

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
2. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139-154
3. Leidy NK, Palmer C, Murray M, et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: psychometric performance of four self-report measures. J Affect Disord 1998;48:207-214
4. Dinan TG. Lithium in bipolar mood disorder. BMJ 2002;324:989-990
5. Hirschfeld RM, Vornik LA. Bipolar disorder - costs and comorbidity. Am J Manag Care 2005;11:S85-S90
6. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-495
7. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord 2002;4:398-405
8. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(suppl 4):1-50
9. Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther 2002;24:1668-1676
10. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
11. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
12. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
13. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
14. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-121
15. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585
16. Hirschfeld RMA, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
17. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229-234
18. Keck PE Jr. Bipolar depression: a new role for atypical antipsychotics? Bipolar Disord 2005;7:34-40
19. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-227
20. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000;17:461-477
21. Gianfrancesco F, Pesa J, Wang RH. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Manag Care Pharm 2005;11:220-230
22. Gianfrancesco F, Wang RH, Pesa J. Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value Health 2005;8:471-478
23. Gutierrez B, Meletiche D, Rupnow MF, et al. Mental health cost comparison among patients with bipolar disorder treated with risperidone versus olanzapine or quetiapine in a managed care setting: a propensity-matched cohort study [poster]. Presented at the 10th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 15-18, 2005; Washington, DC
24. Gianfrancesco F, Rajagopalan K. Antipsychotic use and hospitalization in bipolar or manic patients [poster]. Presented at the 10th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 15-18, 2005; Washington, DC
25. Gianfrancesco FD, Rajagopalan K. Treatment adherence with antipsychotics among patients with bipolar or manic disorder [poster]. Presented at the 10th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 15-18, 2005; Washington, DC
26. Lazarus A, Lage MJ, Pesa JA. Hospitalization rates during combination therapy with atypical antipsychotics in bipolar disorder [poster]. Presented at the 9th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-19, 2004; Arlington, Va
27. White R, Simons WR, Bassi R. Economics of persistence with initially prescribed antipsychotic in older psychotic patients and in patients with bipolar disorder [poster]. Presented at the 7th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 19-22, 2002; Arlington, Va
28. Zhu B, Tunis SL, Zhao Z, et al. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin 2005;21:555-564
29. Revicki DA, Paramore LC, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64:288-294
30. Price N, Davey P, Mudge M, et al. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia [poster]. Presented at the 9th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 16-19, 2004; Arlington, Va
31. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: results from a randomized controlled trial. J Affect Disord 2002;69:109-118
32. Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8:1-187
33. McGarry LJ, Bird A, Thompson D, et al. Cost-effectiveness of atypical antipsychotics in acute bipolar mania [poster]. Presented at the 8th annual international meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-21, 2003; Arlington, Va
34. McGarry LJ, Thompson D, Knudsen AP, et al. Cost-effectiveness of competing antipsychotic monotherapies in acute bipolar mania in the UK [poster]. Presented at the 7th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research; October 24-26, 2004; Hamburg, Germany
35. Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006;163:2047-2056
36. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17
37. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-2089
38. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004;8:1-192
39. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-890
40. Coyle D, Tosteson AN. Towards a reference case for economic evaluation of osteoporosis treatments. J Rheumatol Suppl 2003;68:31-36
41. Fleurence RL, Dixon JM, Revicki DA. Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS Drugs 2006;20:591-599
42. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316:61-66
43. Dundar Y, Dodd S, Williamson P, et al. Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: does it make a difference? Int J Technol Assess Health Care 2006;22:288-294